Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | DPP4 | P27487 | 3/20 | 0.49 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | PREP | P48147 | 6/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14073993 | 0.98 | GAA (0.61) | GAAMAPTTSHRHPGDDPP4 | |
| SCHEMBL14085098 | 0.87 | GAA (0.58) | GAAMAPTTSHRHPGDDPP4 | |
| SCHEMBL30358019 | 0.85 | SMYD3 (0.52) | GAAMAPTTSHRHPGDDPP4 | |
| SCHEMBL30357970 | 0.84 | SMYD3 (0.53) | GAAMAPTTSHRHPGDDPP4 | |
| SCHEMBL4996044 | 0.83 | GAA (0.50) | GAAMAPTTSHRHPGDPOLB | |
| SCHEMBL4995170 | 0.83 | GAA (0.50) | GAAMAPTTSHRHPGDPOLB | |
| SCHEMBL5002824 | 0.83 | GAA (0.50) | GAAMAPTTSHRHPGDPOLB | |
| SCHEMBL5002696 | 0.83 | GAA (0.50) | GAAMAPTTSHRHPGDPOLB | |
| SCHEMBL5005176 | 0.83 | GAA (0.50) | GAAMAPTTSHRHPGDPOLB | |
| SCHEMBL7712960 | 0.82 | GAA (0.59) | GAAMAPTDPP4FAPHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2008-09-11 | — | — | US | disclosed |
| CN-101103019-A | 2- (Cyclic aminocarbonyl) indoline derivative and pharmaceutical composition containing same | DAINIPPON SUMITOMO PHARMA CO (JP) | 2008-01-09 | — | — | CN | disclosed |
| EP-1840126-A1 | 2-(CYCLIC AMINOCARBONYL)INDOLINE DERIVATIVE AND MEDICINAL COMPOSITION CONTAINING THE SAME | Dainippon Sumitomo Pharma Co., Ltd. (JP) | 2007-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221114-A1 | 2-(Cyclic Aminocarbonyl) Indoline Derivative and Medicinal Composition Containing the Same | CYP11B2, CYP11B1, GRIN2A | GAA 3365/4885MAPT 549/4885TSHR 460/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.